BioLineRx Ltd. (BLRX) shares surged 45.88 percent to $5.66, up $1.83 on Friday, after announcing that new data from its Phase 2 CheMo4METPANC clinical trial will be presented at the 2025 ASCO Annual Meeting. BioLineRx is currently trading at $7.11, compared to a previous close of $3.88 on the Nasdaq. The stock opened at $5.80 and has ranged between $5.25 and $7.77 on the day, with trading volume exceeding 26.5 million shares. Its 52-week range is $2.30 to $35.60.
The trial evaluates BioLineRx's CXCR4 inhibitor motixafortide in combination with the PD-1 inhibitor cemiplimab and standard chemotherapies for first-line treatment of pancreatic cancer. Updated results from the pilot phase showed that four of eleven patients remained progression-free for over a year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.